Netherlands-based Pharming Group today released positive top-line results of data from its Phase III clinical trial ...

Data consistent with the improvements seen in the previously reported randomized controlled trial in adolescent and adult APDS patients ...

The FDA has approved PI3Kδ inhibitor Joenja for treating APDS in patients aged 12 or over and, according to Pharming, the treatment is due to be launched in early April. A decision on the drug in ...

selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). Leniolisib, marketed under the brand ...

In contrast to prior PI3Kδ inhibitors, roginolisib dosing did not require dose modifications. Roginolisib is well tolerated over long periods of treatment, up to 4.5 years. Median overall ...

Two therapeutic candidates have progressed into mid-stage clinical development: roginolisib is the first allosteric modulator of PI3Kδ; and cambritaxestat is the only autotaxin inhibitor in ...

giving it an advantageous pharmacology profile and an unprecedented safety profile compared to previous generations of PI3Kδ inhibitors. Roginolisib is being investigated in solid and hematological ...

Onctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today provides a clinical update on its lead asset, roginolisib. Results from the completed Phase I ...